Alpha DNA Investment Management LLC purchased a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,778 shares of the medical instruments supplier's stock, valued at approximately $725,000.
Several other institutional investors and hedge funds have also bought and sold shares of PODD. Stifel Financial Corp boosted its position in shares of Insulet by 2.8% in the 3rd quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier's stock worth $2,450,000 after purchasing an additional 290 shares in the last quarter. MML Investors Services LLC raised its stake in Insulet by 9.3% during the 3rd quarter. MML Investors Services LLC now owns 2,655 shares of the medical instruments supplier's stock valued at $618,000 after buying an additional 225 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Insulet during the 3rd quarter valued at $616,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Insulet in the 3rd quarter worth $114,000. Finally, Tidal Investments LLC grew its holdings in shares of Insulet by 5.2% in the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier's stock worth $2,180,000 after acquiring an additional 466 shares during the period.
Insider Activity at Insulet
In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.47% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of research firms have issued reports on PODD. Royal Bank of Canada assumed coverage on Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target for the company. StockNews.com cut shares of Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Stifel Nicolaus boosted their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, Citigroup lifted their target price on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Insulet has a consensus rating of "Moderate Buy" and an average price target of $292.06.
Read Our Latest Stock Analysis on Insulet
Insulet Price Performance
PODD stock traded up $2.55 during mid-day trading on Wednesday, hitting $246.57. The company had a trading volume of 169,582 shares, compared to its average volume of 713,758. The company has a market capitalization of $17.32 billion, a price-to-earnings ratio of 42.59, a P/E/G ratio of 3.62 and a beta of 1.30. The company has a 50-day moving average price of $261.71 and a 200 day moving average price of $261.16. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.
Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.
About Insulet
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Further Reading
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
